Study type: Human research · Status: Verified against declared source
Nasal Levels of Antimicrobial Chemical sequences in Allergic Asthma Patients and Healthy Controls: Differences and Effect of a Short 1,25(OH)2 Vitamin D3 Treatment.
PloS one · 2015
Study scale: For the first case-control part of our study we aimed to include twenty allergic intermittent asthmatic patients and twenty healthy controls.
Abstract only: Open source record
Product or molecular entity relationships
- LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Our study had two objectives: First, we examined the expression of AMP levels in nasal secretions from patients with allergic asthma and in healthy controls in a case control design.
Methods
Our study had two objectives: First, we examined the expression of AMP levels in nasal secretions from patients with allergic asthma and in healthy controls in a case control design.
Scale or participants
For the first case-control part of our study we aimed to include twenty allergic intermittent asthmatic patients and twenty healthy controls.
Key findings
The levels of antimicrobial peptides in nasal secretions were compared between 19 allergic asthma patients and 23 healthy controls.
Limitations and uncertainty
Vitamin D has been identified as a key regulator of production of AMPs such as the cathelicidin (hCAP18/LL-37) and the neutrophil gelatinase-associated lipocalin (LCN2) in epithelial cells[11,12].
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.